Navigation Links
Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
Date:10/17/2011

OSAKA, Japan, Oct. 18, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc. ("TGRD U.S."), and Takeda Global Research & Development Centre (Europe), Ltd. ("TGRD Europe"), announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes. The program will be conducted across the United States (U.S.), Latin America, and Europe. TAK-875 is the first GPR40 agonist to reach late stage (Phase 3) clinical development.

Completed studies of TAK-875, discovered by Takeda, have suggested glucose-lowering effects in patients with type 2 diabetes by enhancing glucose-dependent insulin secretion.

"Takeda is committed to enhancing the clinical investigation of TAK-875 in order to accelerate the development of a potential new type 2 diabetes treatment option for patients and healthcare professionals," said Thomas Strack, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc., U.S. "An outcome of our robust focus on diabetes over many years, TAK-875 was discovered by Takeda based on our GPCR research and is the first GPR40 agonist to reach late stage (Phase 3) clinical development. TAK-875 is being developed globally, with Phase 3 trials already underway in Japan."

The first Phase 3 trial in the U.S./Europe program, a double-blind, randomized, 24-week safety and efficacy study, will enroll approximately 450 patients with type 2 diabetes who are not adequately controlled on diet and exercise, at approximately 140 sites in the U.S., Latin America, and Europe. The study's primary endpoint will be the change in HbA1c at week 24 while other endpoints will include the assessment of a clinically meaningful response based on reaching HbA1c targets, changes in fasting plasma glucose (FPG) and two-hour postprandial plasma glucose (PPG). Results are ex
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Completes Acquisition and Names New CEO of Nycomed
2. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
3. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
4. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
5. Takeda to Acquire Nycomed
6. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
7. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
8. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
9. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
10. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
11. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SAN DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... ended June 30, 2015.  Revenue for the quarter was ... quarter ended June 30, 2014 (a 17 percent increase ... million, consistent with the quarter ended June 30, 2014. ... consistent with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... , July 30, 2015  EP Global Communications, ... have recently contacted the Company about discussing EPGL,s ... early as Monday, August 3, 2015.  Novartis CEO ... saying that the coming electronic contact lens market ... over the next several years.  Novartis partnered with ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... Bayer HealthCare Pharmaceuticals, Inc. today announced that its ... from Algeta ASA, has been granted Fast Track ... (FDA) for the treatment of castration-resistant (hormone-refractory) prostate ... Radium-223 chloride is an investigational agent and is ...
... Menicon Company Ltd. announced on August 23 the appointment ... Affairs for Menicon Holdings B.V. Dr. Choo will oversee the ... affairs for the company,s growing specialty lens portfolio. ... Leader at Adventus Technology Inc. and the Brien Holden Vision ...
Cached Medicine Technology:FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone 2FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone 3Jennifer Choo Joins Menicon as Specialty Lens Clinical Manager 2
(Date:8/1/2015)... ... ... The condition where veins are enlarged and gnarled is known as varicose veins, ... who spend a lot of time on their feet and standing are even more ... can to create awareness and provide a cure in observance of Senior Citizen's Day ...
(Date:8/1/2015)... ... 01, 2015 , ... Brig and Lita Hart, icons of the network marketing ... Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been a ... have agreed to join their missions of purpose together to change the course of ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to ... , The app is designed to track various metrics of wellness, including physical activity, ... health and use this information for positive behavior modification. Lume Wellness keeps track of ...
(Date:8/1/2015)... ... 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut ... Trail by stepping off Springer Mountain and heading north. Since that day, Phil has ... Connecticut and was greeted by friends and family. He visited CCAR and left an ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and warm-season ... type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. ... introduction of this new type of sod, Super-Sod is giving away red Adirondack chairs ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... Nairobi , London ... LAUSANNE, Switzerland, April 23 To honor the ... Vestergaard Frandsen is stepping up production of its best selling bed ... against insecticide resistant mosquitoes. Malaria claims more than one million lives ...
... in California and Texas, have recovered from unique virus ... in California and Texas have now been diagnosed with ... said Thursday. , All seven people have recovered, Dr. ... Control and Prevention,s National Center for Immunization and Respiratory ...
... April 23 As federal policymakers pursue healthcare reform ... promotion and disease prevention will be critically evaluated. ... than 40 of North America,s top medical schools will ... scientific research in the area of integrative medicine. ...
... (CT, MRI and nuclear medicine) can be significantly reduced ... physicians of the risks, benefits and alternatives of various ... Island University Hospital in Staten Island, NY. ... studies and increasing costs of medical imaging we hypothesized ...
... strong relationship with their parents may start drinking at a ... of developing alcohol problems, a new study suggests. , The ... of Studies on Alcohol and Drugs , underscore the important ... Past studies have suggested that the age at which kids ...
... a small, expandable device inserted inside the breast to ... a potential complication of such devices. The research, led ... Cancer Center and Fort Myers, Florida-based 21st Century Oncology, ... pockets of fluid that build with the use of ...
Cached Medicine News:Health News:Working Towards 'Counting Malaria Out' Through Scale-Up of PermaNet(R) Bed Nets, Vestergaard Frandsen Produces 175 Millionth Net; Introduces New Net To Combat Insecticide Resistance 2Health News:Working Towards 'Counting Malaria Out' Through Scale-Up of PermaNet(R) Bed Nets, Vestergaard Frandsen Produces 175 Millionth Net; Introduces New Net To Combat Insecticide Resistance 3Health News:Swine Flu Cases Now Total 7: CDC 2Health News:Advancements in Integrative Medicine Research to Be Evaluated by Scientists From Leading International Academic Health Centers 2Health News:Good relationship with parents may prevent teen drinking problems 2Health News:Radiation device in the breast reduces complications for early stage breast cancer patients 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: